News
-
21Dec. 2021רוש רוכשת מליניאג’ את זכויות הפיתוח והשיווק של סלקיור
חברת ליניאג’ האמריקאית הנסחרת בבורסה בתל אביב הודיעה כי חתמה על עסקה עם חברת ג’ננטק מקבוצת תאגיד הבריאות רוש, לפיו רוש תפתח, תייצר ותשווק את המוצרים של חברת ‘סלקיור מקבוצת…
-
20Dec. 2021Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement…
-
11Oct. 2021Three Israeli hospitals make Newsweek’s list of top cardiology centers
World’s Best Specialized Hospitals – Cardiology 2021 – Newsweek” includes Hadassah Hospital Heart Institute at Ein Kerem in Jerusalem in a ranking of top-tier global medical centers.
-
16Jun. 2021KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Proceeds will enable further clinical development of DSP107, a first-in-class CD47x41BB targeting fusion protein, for the treatment of solid and hematological tumors and accelerate the path towards clinical development of…
-
2Jun. 2021
-
8Apr. 2021Hadassah and MyBiotics to Collaborate for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy
We are pleased to announce Hadassah important collaboration with MyBiotics for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy
-
10Feb. 2021פיתוח חדש יאפשר לראשונה מעקב בזמן אמת במהלך ניתוחי מוח מורכבים
הטכנולוגיה נולדה בתוכנית ביודיזיין של האוניברסיטה העברית בשיתוף המרכז הרפואי הדסה
-
19Jan. 2021Israel’s BrainWatch Tech is working on prototype of device that will automatically measure and record pupillary reactions to light in patients with severe brain injury
This is the forurh (!) biodesignIsrael company raising seed, coming out of Hadassah and Hebrew University.
-
15Nov. 2020KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors
Congratulations to KAHR & Hadasit Bio Holdings (HBL) our portfolio company for announcing First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of…
-
11Oct. 2020Hadassah, Hebrew University and SHL collaboration for developing AI tools in telemedicine
A joint effort is underway to develop AI tools for predicting future life-threatening cardiac events based on full 12 Lead ECG monitoring. Among the team of researchers from the Cardiology…